Darío Kivelevitch

Baylor University Medical Center — United States

Immunology and Microbiology · Life Sciences

20h-index3.3kcitations52works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(37), Dermatology and Skin Diseases(21), Autoimmune Bullous Skin Diseases(8), Pharmaceutical studies and practices(6), Health Systems, Economic Evaluations, Quality of Life(5)

Publications52 total

Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX.
PubMed·2026
Response to Choi et al, “Pathergy beyond neutrophilic dermatoses: A case of localized leukemia cutis at the site of intravenous infiltration”
JAAD Case Reports·2025Open Access
Refractory cutaneous pseudolymphoma treated with tapinarof
Baylor University Medical Center Proceedings·2025· 1 citedOpen Access
A linear purpuric rash in an elderly man
JAAD Case Reports·2025Open Access
Carcinoma erysipeloides secondary to male breast cancer in a patient with BRCA1 and BRCA2 mutations: a clinical presentation and management
BMJ Case Reports·2025· 1 cited
Absolute Risk of Type II Diabetes Mellitus After Presentation of Associated Cutaneous Disorders: A Retrospective Review
Archives of Dermatological Research·2024
Updates in the prevention of glucocorticoid-induced adverse effects
Dermatology Online Journal·2024Open Access
Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study
Journal of the American Academy of Dermatology·2024· 9 citedOpen Access
More Than Meets the Eye: Localized Bullous Eruption After Transfusion
SKIN The Journal of Cutaneous Medicine·2024Open Access
The use of secukinumab in patients with chronic infections
JEADV Clinical Practice·2024Open Access
Psoriasis as a Risk Factor for Skin Cancer: An International, Propensity-Matched Retrospective Cohort Study
Medical Research Archives·2024Open Access
The Consideration of Cyclosporine in the Treatment of Stevens-Johnson Syndrome
JAMA Dermatology·2023
IL-17 and -23 Inhibitors for the Treatment of Psoriasis
EMJ Allergy & Immunology·2023· 9 citedOpen Access
25363 Serious infections and infections related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials
Journal of the American Academy of Dermatology·2021
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Dermatology and Therapy·2021· 91 citedOpen Access
Brodalumab
2020
Ixekizumab in the treatment of moderate‐to‐severe plaque psoriasis: Patient adherence, satisfaction, and preferences
Dermatologic Therapy·2020· 11 cited
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures
Journal of the American Academy of Dermatology·2020· 308 cited
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies
Journal of the American Academy of Dermatology·2020· 315 cited
Joint AAD-NPF Guidelines of Care for the Management of Psoriasis With Systemic Non-Biological Therapies
Journal of the American Academy of Dermatology·2020· 7 cited
page 1 of 3Next →

Frequent Co-authors

Alan Menter(34), Nehal N. Mehta(8), Bruce Strober(7), Daniel H. Kaplan(7), Benjamin K. Stoff(7), April W. Armstrong(7), Cody Connor(7), Kelly M. Cordoro(7), Boni E. Elewski(7), Joel M. Gelfand(7), Kenneth B. Gordon(7), Alice B. Gottlieb(7), Matthew Kiselica(7), Neil J. Korman(7), Daniela Kroshinsky(7), Mark Lebwohl(7), Craig L. Leonardi(7), Jason Lichten(7), Henry W. Lim(7), Amy S. Paller(7)